文献速递白血病

miR-155通过抑制干扰素反应促进FLT3-ITD诱导的骨髓增殖性疾病

miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
PubMed 文献 · Blood · 2017-04-21

研究利用遗传小鼠模型发现,miR-155促进FLT3-ITD诱导的骨髓、脾和外周血髓系扩增,机制涉及靶向Cebpb并降低干扰素反应的生长抑制作用;FLT3-ITD+急性髓系白血病(AML)临床样本miR-155水平显著高于FLT3-WT AML且干扰素反应更低,抑制miR-155可升高干扰素反应并减少集落形成。

要点

  • miR-155促进FLT3-ITD诱导的骨髓、脾和外周血髓系扩增。
  • miR-155通过靶向Cebpb降低干扰素反应的生长抑制作用。
  • FLT3-ITD+ AML样本miR-155高且干扰素反应低,抑制miR-155可减少集落形成。

核心结论

  • miR-155与FLT3-ITD协同促进体内髓系细胞扩增,机制包括抑制干扰素信号的多靶点机制。

研究设计与样本

  • 研究采用遗传小鼠模型确定miR-155是否影响FLT3-ITD诱导的骨髓增殖性疾病的发展。

主要发现

  • miR-155促进FLT3-ITD诱导的骨髓、脾和外周血髓系扩增。
  • miR-155通过减少干扰素反应的生长抑制作用增加造血干/祖细胞群的增殖,并涉及靶向Cebpb。
  • 与FLT3-WT AML样本相比,原代FLT3-ITD+ AML临床样本的miR-155水平显著更高且干扰素反应更低。
  • 使用CRISPR/Cas9抑制FLT3-ITD+ AML细胞系中的miR-155,或使用锁核酸反义抑制剂抑制原代FLT3-ITD+ AML样本中的miR-155,均导致干扰素反应升高并减少集落形成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

FLT3-ITD+ acute myeloid leukemia (AML) accounts for ∼25% of all AML cases and is a subtype that carries a poor prognosis. microRNA-155 (miR-155) is specifically overexpressed in FLT3-ITD+ AML compared with FLT3 wild-type (FLT3-WT) AML and is critical for the growth of FLT3-ITD+ AML cells in vitro. However, miR-155's role in regulating FLT3-ITD-mediated disease in vivo remains unclear. In this study, we used a genetic mouse model to determine whether miR-155 influences the development of FLT3-ITD-induced myeloproliferative disease. Results indicate that miR-155 promotes FLT3-ITD-induced myeloid expansion in the bone marrow, spleen, and peripheral blood. Mechanistically, miR-155 increases proliferation of the hematopoietic stem and progenitor cell compartments by reducing the growth-inhibitory effects of the interferon (IFN) response, and this involves targeting of Cebpb. Consistent with our observations in mice, primary FLT3-ITD+ AML clinical samples have significantly higher miR-155 levels and a lower IFN response compared with FLT3-WT AML samples. Further, inhibition of miR-155 in FLT3-ITD+ AML cell lines using CRISPR/Cas9, or primary FLT3-ITD+ AML samples using locked nucleic acid antisense inhibitors, results in an elevated IFN response and reduces colony formation. Altogether, our data reveal that miR-155 collaborates with FLT3-ITD to promote myeloid cell expansion in vivo and that this involves a multitarget mechanism that includes repression of IFN signaling.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wallace JA, Kagele DA, Eiring AM, et al. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood. 2017. PMID: 28432220. doi:10.1182/blood-2016-09-740209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。